Biotech psychedelics company Small Pharma Inc. (OTCQB:DMTTF) has received an Issue Notification from the United States Patent and Trademark Office (USPTO) confirming that its patent application for novel injectable formulations of DMT-based compounds has been approved and will be granted as of August 9, 2022 in the United States.
“We believe that this patent, covering our two most advanced DMT programs, SPL026 and SPL028, will provide protection of those assets until August 2041. We have focused on protecting our pipeline assets through novel chemistry and, in this case, optimized finished dosage forms," said chief of innovation and IP officer Peter Rands.
.png?w=600)
